Roche has signed a deal to exclusively license two Inovio Pharmaceuticals (INO) vaccines - INO-5150 for prostate cancer and INO-1800 for hepatitis B, both of which are in pre-clinical development.
Roche will pay $10M up front, milestones of up to $412.5M, and double-digit tiered royalties on any product sales.
Inovio's vaccines have shown that they can induce the immune system's T cells in animal models to fight disease.
The Swiss company will also gain access to Inovio's electroporation technology, which is used to administer the vaccines.
Inovio shares soar 33% premarket, Roche +1% in Zurich. (PR)